When to withhold oral anticoagulation in atrial fibrillation – an overview of frequent clinical discussion topics

References

• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. doi:10.1093/eurheartj/ehw21027567408
   PubMed Web of Science ®Google Scholar
• Martin A, Siegal D, Verbrugge F, et al. Why do clinicians withhold anticoagulation in patients with atrial fibrillation and CHA2DS2-VASc score ≥2? Arch Cardiovasc Dis Suppl. 2019;11(1):83–84. doi:10.1016/j.acvdsp.2018.10.184
   Google Scholar
• Pisters R, van Vugt SPG, Brouwer MA, et al. Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. Neth Heart J. 2017;25(10):551–558. doi:10.1007/s12471-017-1009-928674871
   PubMed Web of Science ®Google Scholar
• Bahri O, Roca F, Lechani T, et al. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015;63(1):71–76. doi:10.1111/jgs.1320025597559
   PubMed Web of Science ®Google Scholar
• Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746–2751. doi:10.1093/eurheartj/eht28023900699
   PubMed Web of Science ®Google Scholar
• Son MK, Lim NK, Park HY. Trend of prevalence of atrial fibrillation and use of oral anticoagulation therapy in patients with atrial fibrillation in South Korea (2002-2013). J Epidemiol. 2018;28(2):81–87. doi:10.2188/jea.JE2016014929109364
   PubMed Web of Science ®Google Scholar
• Proietti M, Laroche C, Nieuwlaat R, et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: a comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018;55:28–34. doi:10.1016/j.ejim.2018.05.01629778588
   PubMed Web of Science ®Google Scholar
• O’Brien EC, Holmes DN, Ansell JE, et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014;167(4):601–609. e601. doi:10.1016/j.ahj.2013.12.01424655711
   PubMed Web of Science ®Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393. doi:10.1093/eurheartj/ehy13629562325
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi:10.1378/chest.09-158419762550
   PubMed Web of Science ®Google Scholar
• Lubitz SA, Khurshid S, Weng LC, et al. Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. Am Heart J. 2018;200:24–31. doi:10.1016/j.ahj.2018.03.00329898845
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100. doi:10.1378/chest.10-013420299623
   PubMed Web of Science ®Google Scholar
• Wilke T, Groth A, Mueller S, et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost. 2012;107(6):1053–1065. doi:10.1160/TH11-11-076822398417
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost. 2017;117(7):1448–1454. doi:10.1160/TH16-12-096128331926
   PubMed Web of Science ®Google Scholar
• Pisters R, van Oostenbrugge RJ, Knottnerus IL, et al. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace. 2010;12(6):779–784. doi:10.1093/europace/euq08020348143
   PubMed Web of Science ®Google Scholar
• Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235–240. doi:10.1161/STROKEAHA.108.51634418757287
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395–401. doi:10.1016/j.jacc.2011.03.03121757117
   PubMed Web of Science ®Google Scholar
• Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713–719. doi:10.1016/j.ahj.2005.04.01716504638
   PubMed Web of Science ®Google Scholar
• Fox KAA, Lucas JE, Pieper KS, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7(12):e017157. doi:10.1136/bmjopen-2017-017157
   PubMed Web of Science ®Google Scholar
• Jaspers Focks J, van Vugt SP, Albers-Akkers MT, et al. Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists. J Thromb Haemost. 2016;14(9):1715–1724. doi:10.1111/jth.1336127172860
   PubMed Web of Science ®Google Scholar
• Bassand JP, Accetta G, Al Mahmeed W, et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation. PLoS One. 2018;13(1):e0191592. doi:10.1371/journal.pone.019159229370229
   PubMed Web of Science ®Google Scholar
• Marcucci M, Lip GY, Nieuwlaat R, Pisters R, Crijns HJ, Iorio A. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. Am J Med. 2014;127(10):979–986. ( e972). doi:10.1016/j.amjmed.2014.05.00324838192
   PubMed Web of Science ®Google Scholar
• Peacock WF, Tamayo S, Patel M, Sicignano N, Hopf KP, Yuan Z. CHA2DS2-VASc scores and major bleeding in patients with nonvalvular atrial fibrillation who are receiving rivaroxaban. Ann Emerg Med. 2017;69(5):541–550 (e541). doi:10.1016/j.annemergmed.2016.09.032
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Oldgren J, Lindback J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387(10035):2302–2311. doi:10.1016/S0140-6736(16)00741-827056738
   PubMed Web of Science ®Google Scholar
• O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36(46):3258–3264. doi:10.1093/eurheartj/ehv47626424865
   PubMed Web of Science ®Google Scholar
• Shoemaker MB, Stevenson WG. The ABC death risk score: is it time to start measuring GDF-15? Eur Heart J. 2018;39(6):486–487. doi:10.1093/eurheartj/ehx64229136146
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Lindback J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37(20):1582–1590. doi:10.1093/eurheartj/ehw05426920728
   PubMed Web of Science ®Google Scholar
• Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151(5):297–305. doi:10.7326/0003-4819-151-5-200909010-0000319721017
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125(19):2298–2307. doi:10.1161/CIRCULATIONAHA.111.05507922514252
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106(4):739–749. doi:10.1160/TH11-05-036421789337
   PubMed Web of Science ®Google Scholar
• Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584–589. doi:10.1160/TH11-11-078422186961
   PubMed Web of Science ®Google Scholar
• Chan PH, Huang D, Lau CP, et al. Net clinical benefit of dabigatran over warfarin in patients with atrial fibrillation stratified by CHA2DS2-VASc and time in therapeutic range. Can J Cardiol. 2016;32(10):1247e1215–1247 e1221. doi:10.1016/j.cjca.2016.01.016
   Web of Science ®Google Scholar
• Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011;13(5):723–746. doi:10.1093/europace/eur12621515596
   PubMed Web of Science ®Google Scholar
• Bayer plc. Xarelto summary of product characteristics; 2018 Available from: https://www.medicines.org.uk/emc/product/2793/smpc. Accessed 828, 2019.
   Google Scholar
• Boehringer Ingelheim Limited. Pradaxa summary of product characteristics; 2018 Available from: https://www.medicines.org.uk/emc/product/4703/smpc. Accessed 828, 2019
   Google Scholar
• Bristol-Myers Squibb-Pfizer. Eliquis Summary of Product Characteristics; 2018 Available from: https://www.medicines.org.uk/emc/product/2878/smpc. Accessed 828, 2019
   Google Scholar
• Daiichi Sankyo UK Limited. Lixiana summary of product characteristics; 2019 Available from: https://www.medicines.org.uk/emc/product/6905/smpc. Accessed 828, 2019.
   Google Scholar
• Douros A, Renoux C, Yin H, Filion KB, Suissa S, Azoulay L. Concomitant use of direct oral anticoagulants with antiplatelet agents and the risk of major bleeding in patients with nonvalvular atrial fibrillation. Am J Med. 2019;132(2):191–199 e112. doi:10.1016/j.amjmed.2018.10.00830691551
   PubMed Web of Science ®Google Scholar
• van Rein N, Heide-Jorgensen U, Lijfering WM, Dekkers OM, Sorensen HT, Cannegieter SC. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation. 2019;139(6):775–786. doi:10.1161/CIRCULATIONAHA.118.03624830586754
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Heidbuchel H. The significance of drug-drug and drug-food interactions of oral anticoagulation. Arrhythm Electrophysiol Rev. 2018;7(1):55–61. doi:10.15420/aer.2017.50.129636974
   PubMed Web of Science ®Google Scholar
• Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;63(9):891–900. doi:10.1016/j.jacc.2013.11.01324315894
   PubMedGoogle Scholar
• Grodensky CA, Golin CE, Ochtera RD, Turner BJ. Systematic review: effect of alcohol intake on adherence to outpatient medication regimens for chronic diseases. J Stud Alcohol Drugs. 2012;73(6):899–910. doi:10.15288/jsad.2012.73.89923036207
   PubMed Web of Science ®Google Scholar
• Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology. 2016;151(6):1105–1112. e1110. doi:10.1053/j.gastro.2016.08.05427639805
   PubMed Web of Science ®Google Scholar
• Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. 2018;320(21):2221–2230. doi:10.1001/jama.2018.1724230512099
   PubMed Web of Science ®Google Scholar
• Bennaghmouch N, de Veer A, Bode K, et al. Efficacy and safety of the use of non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation and concomitant aspirin therapy: a meta-analysis of randomized trials. Circulation. 2018;137(11):1117–1129. doi:10.1161/CIRCULATIONAHA.117.02851329101289
   PubMed Web of Science ®Google Scholar
• Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–1115. doi:10.1016/S0140-6736(12)62177-123415013
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–2434. doi:10.1056/NEJMoa161159427959713
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–1524. doi:10.1056/NEJMoa170845428844193
   PubMed Web of Science ®Google Scholar
• Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–1524. doi:10.1056/NEJMoa181708330883055
   PubMed Web of Science ®Google Scholar
• Piccini JP, Jones WS. Triple therapy for atrial fibrillation after PCI. N Engl J Med. 2017;377(16):1580–1582. doi:10.1056/NEJMe171075329045197
   PubMed Web of Science ®Google Scholar
• Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61(25):2551–2556. doi:10.1016/j.jacc.2013.03.03523583249
   PubMed Web of Science ®Google Scholar
• Boersma LV, Ince H, Kische S, et al. Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology. Circ Arrhythm Electrophysiol. 2019;12(4):e006841. doi:10.1161/CIRCEP.118.00684130939908
   PubMed Web of Science ®Google Scholar
• Nishimura M, Sab S, Reeves RR, Hsu JC. Percutaneous left atrial appendage occlusion in atrial fibrillation patients with a contraindication to oral anticoagulation: a focused review. Europace. 2018;20(9):1412–1419. doi:10.1093/europace/eux31329228158
   PubMed Web of Science ®Google Scholar
• Gattellari M, Worthington JM, Zwar NA, Middleton S. The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey. BMC Fam Pract. 2008;9:62. doi:10.1186/1471-2296-9-6219014560
   PubMed Web of Science ®Google Scholar
• Proietti M, Romiti GF, Romanazzi I, et al. Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2018;261:84–91. doi:10.1016/j.ijcard.2018.03.05329572080
   PubMed Web of Science ®Google Scholar
• Smit MD, Van Gelder IC. Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation. Evid Based Med. 2017;22(3):107–108. doi:10.1136/ebmed-2017-11069428512109
   PubMedGoogle Scholar
• Hernandez I, Zhang Y, Brooks MM, Chin PK, Saba S. Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation. Stroke. 2017;48(1):159–166. doi:10.1161/STROKEAHA.116.01515027909200
   PubMed Web of Science ®Google Scholar
• Xu Y, Shoamanesh A, Schulman S, et al. Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: global survey of the practices of neurologists, neurosurgeons and thrombosis experts. PLoS One. 2018;13(1):e0191137. doi:10.1371/journal.pone.019113729370183
   PubMed Web of Science ®Google Scholar
• Kappelle LJ, Hofmeijer J, Chamuleau SA, van Nieuwenhuizen KM, Hemels ME, Klijn CJ. [Resumption of antithrombotic treatment after an intracerebral haemorrhage]. Ned Tijdschr Geneeskd. 2015;159:A8507.25873219
   PubMedGoogle Scholar
• Li YG, Lip GYH. Anticoagulation resumption after intracerebral hemorrhage. Curr Atheroscler Rep. 2018;20(7):32. doi:10.1007/s11883-018-0733-y29781063
   PubMed Web of Science ®Google Scholar
• Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824–836. doi:10.1001/jama.2015.084625710659
   PubMed Web of Science ®Google Scholar
• Nielsen PB, Larsen TB, Skjoth F, Lip GY. Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation. JAMA Intern Med. 2017;177(4):563–570. doi:10.1001/jamainternmed.2016.936928241151
   PubMed Web of Science ®Google Scholar
• Murthy SB, Gupta A, Merkler AE, et al. Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis. Stroke. 2017;48(6):1594–1600. doi:10.1161/STROKEAHA.116.01632728416626
   PubMed Web of Science ®Google Scholar
• Murphy MP, Kuramatsu JB, Leasure A, et al. Cardioembolic stroke risk and recovery after anticoagulation-related intracerebral hemorrhage. Stroke. 2018;49(11):2652–2658. doi:10.1161/STROKEAHA.118.02179930355194
   PubMed Web of Science ®Google Scholar
• Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43(6):1511–1517. doi:10.1161/STROKEAHA.112.65061422492518
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014;45(5):1304–1312. doi:10.1161/STROKEAHA.113.00450624743444
   PubMed Web of Science ®Google Scholar
• van Nieuwenhuizen KM, van der Worp HB, Algra A, et al. Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials. 2015;16:393. doi:10.1186/s13063-015-0731-026340977
   PubMed Web of Science ®Google Scholar
• Start or STop Anticoagulants Randomised Trial (SoSTART). Available from: https://clinicaltrials.gov/ct2/show/NCT03153150. Accessed August 28, 2019.
   Google Scholar
• Qureshi W, Mittal C, Patsias I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol. 2014;113(4):662–668. doi:10.1016/j.amjcard.2013.10.04424355310
   PubMed Web of Science ®Google Scholar
• Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med. 2012;172(19):1484–1491. doi:10.1001/archinternmed.2012.426122987143
   PubMedGoogle Scholar
• Sengupta N, Feuerstein JD, Patwardhan VR, et al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol. 2015;110(2):328–335. doi:10.1038/ajg.2014.39825512338
   PubMed Web of Science ®Google Scholar
• Scott MJ, Veitch A, Thachil J. Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when? Br J Haematol. 2017;177(2):185–197. doi:10.1111/bjh.1459928272736
   PubMed Web of Science ®Google Scholar
• Kido K, Scalese MJ. Management of oral anticoagulation therapy after gastrointestinal bleeding: whether to, when to, and how to restart an anticoagulation therapy. Ann Pharmacother. 2017;51(11):1000–1007. doi:10.1177/106002801771701928639882
   PubMed Web of Science ®Google Scholar
• Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr Med. 2011;27(1):1–15. doi:10.1016/j.cger.2010.08.00921093718
   PubMed Web of Science ®Google Scholar
• Oqab Z, Pournazari P, Sheldon RS. What is the impact of frailty on prescription of anticoagulation in elderly patients with atrial fibrillation? A Systematic Review and Meta-Analysis. J Atr Fibrillation. 2018;10(6):1870. doi:10.4022/jafib.187029988282
   PubMedGoogle Scholar
• Wilkinson C, Todd O, Clegg A, Gale CP, Hall M. Management of atrial fibrillation for older people with frailty: a systematic review and meta-analysis. Age Ageing. 2018;48(2):196–203. doi:10.1093/ageing/afy180
   Web of Science ®Google Scholar
• Hylek EM, D’Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006;37(4):1075–1080. doi:10.1161/01.STR.0000209239.71702.ce16527999
   PubMed Web of Science ®Google Scholar
• Gullon A, Formiga F, Diez-Manglano J, et al. Influence of frailty on anticoagulant prescription and clinical outcomes after 1-year follow-up in hospitalised older patients with atrial fibrillation. Intern Emerg Med. 2019;14(1):59–69. doi:10.1007/s11739-018-1938-330191535
   PubMed Web of Science ®Google Scholar
• Banerjee A, Clementy N, Haguenoer K, Fauchier L, Lip GY. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Am J Med. 2014;127(10):972–978. doi:10.1016/j.amjmed.2014.05.03524929021
   PubMed Web of Science ®Google Scholar
• Rao MP, Vinereanu D, Wojdyla DM, et al. Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. Am J Med. 2018;131(3):269–275. e262. doi:10.1016/j.amjmed.2017.10.03629122636
   PubMed Web of Science ®Google Scholar
• Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll Cardiol. 2016;68(11):1169–1178. doi:10.1016/j.jacc.2016.06.03427609678
   PubMed Web of Science ®Google Scholar
• Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118(6):612–617. doi:10.1016/j.amjmed.2005.02.02215922692
   PubMed Web of Science ®Google Scholar
• Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677–685. doi:10.1001/archinte.159.7.67710218746
   PubMedGoogle Scholar
• Subic A, Cermakova P, Religa D, et al. Treatment of atrial fibrillation in patients with dementia: a Cohort Study from the Swedish Dementia Registry. J Alzheimers Dis. 2018;61(3):1119–1128. doi:10.3233/JAD-17057529286925
   PubMed Web of Science ®Google Scholar
• Alonso A, Arenas de Larriva AP. Atrial fibrillation, cognitive decline and dementia. Eur Cardiol. 2016;11(1):49–53. doi:10.15420/ecr.2016:13:227547248
   PubMedGoogle Scholar
• Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J. 2018;39(6):453–460. doi:10.1093/eurheartj/ehx57929077849
   PubMed Web of Science ®Google Scholar